Gara Jalqabaatti › Kansaarii Pirostaatikii Itti Falmu
Qorannoo klinikaalii Kansaarii Pirostaatikii Itti Falmu Ameerikaa Keessatti hirmaatuu
Qorannoo 18 Kansaarii Pirostaatikii Itti Falmu f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- Los Angeles, CAQorannoo 8
- New York City, NYQorannoo 7
- Seattle, WAQorannoo 6
- Houston, TXQorannoo 6
- Boston, MAQorannoo 5
- Philadelphia, PAQorannoo 4
- Pittsburgh, PAQorannoo 4
- Queens, NYQorannoo 4
- Mountain View, CAQorannoo 3
- Minneapolis, MNQorannoo 3
- Myrtle Beach, SCQorannoo 3
- San Diego, CAQorannoo 3
- Metairie, LAQorannoo 3
- Baltimore, MDQorannoo 3
- Nashville, TNQorannoo 3
- Arlington, VAQorannoo 3
- Cincinnati, OHQorannoo 3
- Dallas, TXQorannoo 3
- San Francisco, CAQorannoo 3
- Grand Rapids, MIQorannoo 3
- St. Louis, MOQorannoo 3
Naannoon
- CaliforniaQorannoo 11
- ConnecticutQorannoo 3
- FloridaQorannoo 5
- IllinoisQorannoo 3
- LouisianaQorannoo 3
- MarylandQorannoo 3
- MassachusettsQorannoo 5
- MichiganQorannoo 7
- MinnesotaQorannoo 4
- MissouriQorannoo 3
- NebraskaQorannoo 3
- New JerseyQorannoo 4
- New YorkQorannoo 8
- North CarolinaQorannoo 4
- OhioQorannoo 4
- OregonQorannoo 3
- PennsylvaniaQorannoo 5
- South CarolinaQorannoo 4
- TennesseeQorannoo 5
- TexasQorannoo 7
- VirginiaQorannoo 4
- WashingtonQorannoo 6
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dhiroota · Haaromfame 25-Ful-2026 · NCT07164443A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07225946A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Dhiroota · Haaromfame 24-Ful-2026 · NCT07719361Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT06353386A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT06863272Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Dhiroota · Haaromfame 10-Ful-2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 100 · Dhiroota · Haaromfame 13-Hag-2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Dhiroota · Haaromfame 10-Hag-2026 · NCT06067841A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 115 · Dhiroota · Haaromfame 16-Ado-2026 · NCT07677254A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 115 · Dhiroota · Haaromfame 16-Ado-2026 · NCT07677267A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Dhiroota · Haaromfame 29-Cam-2026 · NCT0725840764Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Dhiroota · Haaromfame 06-Cam-2026 · NCT04868604Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Dhiroota · Haaromfame 13-Elb-2026 · NCT06190899Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dhiroota · Haaromfame 13-Elb-2026 · NCT04337580Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Dhiroota · Haaromfame 21-Sad-2025 · NCT0574362118F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 fi ol · Dhiroota · Haaromfame 27-Sad-2024 · NCT06706921Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.